Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecas79517-01-4

79517-01-4

79517-01-4 structural image
Product Name: Octreotide
Formula: C51H70N10O12S2
Synonyms: SMS 201-995
Inquiry

CHEMICAL AND PHYSICAL PROPERTIES

Boiling Point 1447
Melting Point 153-156

SAFETY INFORMATION

Signal word Warning
Pictogram(s)

Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
Precautionary Statement Codes P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

COMPUTED DESCRIPTORS

Molecular Weight 1019.2 g/mol
XLogP3 1
Hydrogen Bond Donor Count 13
Hydrogen Bond Acceptor Count 14
Rotatable Bond Count 17
Exact Mass 1018.44048069 g/mol
Monoisotopic Mass 1018.44048069 g/mol
Topological Polar Surface Area 383 Ų
Heavy Atom Count 71
Formal Charge 0
Complexity 1740
Isotope Atom Count 0
Defined Atom Stereocenter Count 10
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 1
Compound Is Canonicalized Yes

PRODUCT INTRODUCTION

description

Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.

RELATED SUPPLIERS

NEULAND LABS

1Y
product:Octreotide 98%

USV Pvt Ltd

1Y
product:Octreotide 98%

Piramal Pharma Solutions

1Y
product:Octreotide acetate 79517-01-4 99%

Sun Pharmaceutical Industries Ltd

1Y
product:79517-01-4 Octreotide acetate 98%

Ralington Pharma

1Y
product:79517-01-4 98%

Mylan Laboratories Ltd

1Y
product:Octreotide acetate 98%
All suppliers(6)